December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mereo BioPharma Group plc - American Depositary Shares (NQ:MREO)

1.998 -0.042 (-2.07%)
Streaming Delayed Price Updated: 12:08 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mereo BioPharma Group plc - American Depositary Shares

< Previous 1 2 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
From Mereo BioPharma Group plc
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
Data from Orbit and Cosmic studies expected around the end of the year 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Provides Update on Lead Clinical Programs
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
From Mereo BioPharma Group plc
Via GlobeNewswire
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.